219 related articles for article (PubMed ID: 36339006)
21. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
22. Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma.
Wang W; Ye Y; Zhang X; Ye X; Liu C; Bao L
Front Mol Biosci; 2022; 9():937979. PubMed ID: 35911976
[No Abstract] [Full Text] [Related]
23. Prognostic Signature and Tumor Immune Landscape of N7-Methylguanosine-Related lncRNAs in Hepatocellular Carcinoma.
Wei W; Liu C; Wang M; Jiang W; Wang C; Zhang S
Front Genet; 2022; 13():906496. PubMed ID: 35938009
[TBL] [Abstract][Full Text] [Related]
24. Identification and Validation of a Prognostic lncRNA Signature for Hepatocellular Carcinoma.
Li W; Chen QF; Huang T; Wu P; Shen L; Huang ZL
Front Oncol; 2020; 10():780. PubMed ID: 32587825
[No Abstract] [Full Text] [Related]
25. Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.
Cao J; Wu L; Lei X; Shi K; Shi L; Shi Y
Bioengineered; 2021 Dec; 12(1):673-681. PubMed ID: 33622186
[TBL] [Abstract][Full Text] [Related]
26. Predicting prognosis and immune responses in hepatocellular carcinoma based on N7-methylguanosine-related long noncoding RNAs.
Dai YY; Gao YP; Chen LX; Liu JS; Zeng C; Zhou JD; Wu HL
Front Genet; 2022; 13():930446. PubMed ID: 36110218
[No Abstract] [Full Text] [Related]
27. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
28. Assessment of prognostic role of a novel 7-lncRNA signature in HCC patients.
Qu J; Tao D; Huang W; Lu L; Fan J; Zhang S; Huang F
Heliyon; 2023 Aug; 9(8):e18493. PubMed ID: 37520979
[TBL] [Abstract][Full Text] [Related]
29. Development of the expression and prognostic significance of m
Xu G; Li C; Di Z; Yang Y; Liang L; Yuan Q; Yang Q; Dong X; Xu S; Wu G
Cancer Med; 2023 Mar; 12(6):7667-7681. PubMed ID: 36464884
[TBL] [Abstract][Full Text] [Related]
30. m5C-Related lncRNAs Predict Overall Survival of Patients and Regulate the Tumor Immune Microenvironment in Lung Adenocarcinoma.
Pan J; Huang Z; Xu Y
Front Cell Dev Biol; 2021; 9():671821. PubMed ID: 34268304
[TBL] [Abstract][Full Text] [Related]
31. Identification of an Epithelial-Mesenchymal Transition-Related Long Non-coding RNA Prognostic Signature to Determine the Prognosis and Drug Treatment of Hepatocellular Carcinoma Patients.
Huang S; Li D; Zhuang L; Zhang J; Wu J
Front Med (Lausanne); 2022; 9():850343. PubMed ID: 35685422
[TBL] [Abstract][Full Text] [Related]
32. A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma.
Lin X; Yang S
Adv Clin Exp Med; 2022 Oct; 31(10):1099-1109. PubMed ID: 35581934
[TBL] [Abstract][Full Text] [Related]
33. Novel methylation-related long non-coding RNA clinical outcome prediction method: the clinical phenotype and immune infiltration research in low-grade gliomas.
Li Y; Li X; Yu Z
Front Oncol; 2023; 13():1177120. PubMed ID: 37228500
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.
Wu ZY; Shi ZY
Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162
[TBL] [Abstract][Full Text] [Related]
35. Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.
Dai K; Liu C; Guan G; Cai J; Wu L
BMC Cancer; 2022 May; 22(1):496. PubMed ID: 35513781
[TBL] [Abstract][Full Text] [Related]
36. Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma.
Jin C; Li R; Deng T; Li J; Yang Y; Li H; Chen K; Xiong H; Chen G; Wang Y
Front Mol Biosci; 2021; 8():784553. PubMed ID: 34988119
[TBL] [Abstract][Full Text] [Related]
37. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
[No Abstract] [Full Text] [Related]
38. Construction and Validation of a Ferroptosis-Related lncRNA Signature as a Novel Biomarker for Prognosis, Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma.
Zhang Z; Zhang W; Wang Y; Wan T; Hu B; Li C; Ge X; Lu S
Front Cell Dev Biol; 2022; 10():792676. PubMed ID: 35295858
[TBL] [Abstract][Full Text] [Related]
39. Identification of senescence-associated long non-coding RNAs to predict prognosis and immune microenvironment in patients with hepatocellular carcinoma.
Gao C; Zhou G; Cheng M; Feng L; Cao P; Zhou G
Front Genet; 2022; 13():956094. PubMed ID: 36330438
[No Abstract] [Full Text] [Related]
40. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
Front Immunol; 2021; 12():719175. PubMed ID: 34603293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
